Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
1.340
+0.040 (3.08%)
At close: May 12, 2025, 4:00 PM
1.350
+0.010 (0.75%)
After-hours: May 12, 2025, 7:28 PM EDT
Prime Medicine Stock Forecast
PRME's stock price has decreased by -76.11% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 13.17, with a low estimate of 10 and a high estimate of 18. The average target predicts an increase of 882.84% from the current stock price of 1.34.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2025.
Analyst Ratings
The average analyst rating for Prime Medicine stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 → $16 | Strong Buy | Maintains | $15 → $16 | +1,094.03% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +646.27% | Mar 19, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $10 | Buy | Reiterates | $10 | +646.27% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +646.27% | Mar 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +1,019.40% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
4.68M
from 2.98M
Increased by 56.92%
Revenue Next Year
11.73M
from 4.68M
Increased by 150.59%
EPS This Year
-1.24
from -1.65
EPS Next Year
-1.20
from -1.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.9M | 84.0M | 141.8M | ||
| Avg | 4.7M | 11.7M | 29.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 533.6% | 1,694.5% | 1,108.4% | ||
| Avg | 56.9% | 150.6% | 154.1% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.81 | -0.64 | -0.60 | ||
| Avg | -1.24 | -1.20 | -1.16 | ||
| Low | -1.42 | -1.47 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.